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Abstract
Objectives—Patient-reported outcomes (PRO) help patients, caretakers, clinicians and policy 
makers make informed decisions regarding treatment effectiveness. Our objective was to assess 
the quality of PRO reporting and methodological strengths and weaknesses in randomized 
controlled trials (RCT) in bladder cancer.
Methods—A systematic literature search of bladder cancer RCT published between January 
2004 and March 2014 was performed. Relevant studies were evaluated using a predetermined 
extraction form that included trial demographics, clinical and PRO characteristics, and standards 
of PRO reporting based on recommendations of the International Society for Quality of Life 
Research.
Results—Nine RCTs enrolling 1,237 patients were evaluated. All studies were in patients with 
non-metastatic disease. In 5 RCTs, a PRO was the primary endpoint. The majority of RCTs did 
not report the mode of administration of the PRO instrument or the methods of collecting data. No 
RCT addressed the statistical approaches for missing data.
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Conclusions—We found that few RCTs in bladder cancer report PRO as an outcome. Efforts to 
expand PRO reporting to more RCTs and improve the quality of PRO reporting according to 
recognized standards are necessary for facilitating clinical decision-making.
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bladder cancer; patient-reported outcomes; clinical trials; quality of life; clinical decision-making
1. Introduction
Bladder cancer is the 7th most common cancer in men worldwide, with an estimated total of 
429,793 new cases and 165,068 deaths in 2012[1]. Bladder cancer is more common in the 
western world, and is the 6th most common cancer in the United States, accounting for an 
estimated 74,690 new cases and 15,580 deaths in 2014[2].
Approximately 30% of newly diagnosed patients will have muscle-invasive bladder cancer 
(MIBC), for which neoadjuvant chemotherapy and radical cystectomy with urinary 
diversion are considered the standard-of-care[3]. A subset of patients with non-muscle 
invasive bladder cancer (NMIBC) will progress to invasive disease while many others will 
have a protracted disease course that may include invasive monitoring and intravesical 
treatments[4].
For any stage of bladder cancer, informed decision-making needs to consider objective 
outcome measures with a high level of evidence as well as the patient’s values and 
experience[5]. It is increasingly recognized that patient-reported outcomes (PRO) help 
patients, caretakers, clinicians and policy makers make decisions regarding treatment 
effectiveness[6; 7]. However, previous systematic reviews have noted several weaknesses in 
PRO studies in bladder cancer, including retrospective study design and use of non-validated 
questionnaires[8; 9]. Further, reviews in other cancers have shown poor PRO reporting in 
randomized controlled trials (RCT)[10; 11]. Therefore, standards for reporting PRO in RCTs 
have recently been established[12; 13]. The objective of this review was to identify the 
number of RCTs in bladder cancer that have included PRO as an endpoint, and to assess the 
quality of PRO reporting from these studies.
2. Materials and Methods
2.1. Search strategy and identification of studies
An electronic, systematic literature search using Pubmed/Medline, the Cochrane Library, 
PsycINFO and PsychARTICLES was used to identify RCTs in bladder cancer with a PRO 
component from January 2004 to March 2014. Details of our search strategy used in other 
cancers have been previously described[10; 11; 14]. We limited our search to the last 10 
years because a previous MEDLINE search of the literature from 1966 to January 2004 
found no RCT evaluating PRO after radical cystectomy[9]. Relevant studies listed as 
references were also considered.
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2.2. Selection criteria
English-language RCTs involving adult patients with bladder cancer were included 
regardless of disease stage. Studies had to enroll at least 50 patients to be included. Studies 
of patients undergoing screening or involving patients with benign disease were excluded. 
Conference abstracts were not included. Interventions included any RCT comparing 
conventional treatments. Studies considering psychological intervention or complementary 
or alternative medicine were excluded. Any studies evaluating a PRO either as a primary or 
secondary outcome were included. This included both multidimensional HRQOL outcomes 
and any other type of PRO measuring the impact of an intervention. Studies evaluating only 
treatment adherence or satisfaction were not included.
2.3. Data extraction and type of information analyzed
Data were gathered through the Patient Reported Outcome Measurements Over Time IN 
Oncology (PROMOTION) Registry (http://promotion.gimema.it)[14]. For the purpose of 
this review, two broad types of information were extracted: 1) basic trial demographics and 
clinical and PRO characteristics; and 2) elements of PRO reporting based on 
recommendations from the International Society for Quality of Life Research (ISOQOL)
[12].
3. Results
The systematic literature search yielded 1,682 records (Figure 1). After screening records, 
58 full-text articles were assessed for eligibility of which 48 articles were excluded for being 
non-randomized (n=27), not including PRO (n=14), mixed sample (n=1), screening study 
(n=4), and non-English language (n=2). The result was 10 articles on 9 RCTs that met our 
study criteria enrolling 1,237 patients[15–24]. A summary of the main clinical results and 
PRO findings are presented in Table 1.
All 9 RCTs were performed in patients with non-metastatic disease: 5 in patients with 
NMIBC and 4 in patients with MIBC. In 5 RCTs, a PRO was the primary endpoint. The 
level of PRO reporting based on ISOQOL recommendations is presented in the Supplement 
Table.
Although 8 RCTs identified PRO as an endpoint in the abstract, only 2 stated a PRO 
hypothesis in the introduction. Seven RCTs did not report the mode of PRO administration 
or the methods of collecting data. A major limitation was the handling of missing data. None 
of the studies addressed the statistical approaches for missing data and only 1 stated the 
extent of, or the reasons for, missing data.
Four studies used versions of the EORTC instruments, and 3 studies used a bladder-specific 
instrument. However, 4 studies did not provide the rationale for choice of PRO instrument 
or evidence of PRO instrument validity.
Of the 5 RCT that used PRO as the primary endpoint, 3 described the limitations, 
generalizability and clinical significance of the PRO. All 5 interpreted the PRO in the 
discussion and discussed PRO in the context of other trial endpoints.
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Two trials in patients undergoing radical cystectomy reported PRO differences. In a 
comparison of general plus epidural anesthesia versus general anesthesia alone, general plus 
epidural anesthesia was associated with improved pain control at all measured time points 
within 24 hours after surgery[21]. In a comparison of an early recovery after surgery 
protocol versus a conservative recovery regimen, patients treated with the early recovery 
protocol reported more favorable functioning and symptom scores on several EORTC 
measures on post-operative days 3, 7 and at discharge[18].
One study examined radiotherapy with and without chemotherapy for bladder-sparing 
treatment of MIBC. While this study met our inclusion criteria as a RCT of an intervention 
measuring PRO, this study did not report the instrument used, method or schedule of data 
collection, or PRO results[17].
Three of the 5 trials in NMIBC patients reported PRO differences. During transurethral 
resection of bladder tumors, fewer patients receiving spinal anesthesia with bupivacaine 
reported moderate or severe pain compared to patients receiving sufentanil[20]. However, 
bupivacaine was associated with intense motor blockade and longer time to recovery room 
discharge. A trial of oral anticholinergic therapy versus placebo during induction bacillus 
Calmette-Guerin (BCG) therapy reported more urinary and non-urinary symptoms with 
anticholinergic therapy with no clinical benefit[23]. In a comparison of gemcitabine versus 
one-third dose BCG for maintenance therapy, gemcitabine was associated with better 
functioning and symptoms on univariate but not multivariate analysis[16].
4. Discussion
Although bladder cancer is one of the most common cancers worldwide, there is paucity of 
evidence-based PRO from clinical trials. In the last decade, fewer than 1,300 bladder cancer 
patients were enrolled in a RCT evaluating PRO. Notably, 2 of these 9 studies focused 
primarily on anesthesia and peri-operative pain control rather than bladder cancer outcomes.
In contrast, a large number of RCTs with a PRO component have been conducted in prostate 
and gynecological cancers during a similar time period[10; 11]. Whereas we found no RCT 
in bladder cancer with robust PRO, in prostate and gynecological cancers the rate of high-
quality PRO reporting likely to impact clinical decision-making was found to be 20% and 
32%, respectively.
Historically, there have been few validated instruments in NMIBC or MIBC[8]. The 
EORTC QLQ-NMIBC24 was recently validated for use in clinical trials for intermediate 
and high-risk NMIBC[25]. This instrument was used by 1 of the 5 RCT in NMIBC we 
evaluated, while the other RCT used either ad hoc or generic cancer questionnaires. In 
MIBC, new instruments for evaluating the effects of radical cystectomy have recently been 
validated, including the Bladder Cancer Index and the Functional Assessment of Cancer 
Therapy-Vanderbilt Cystectomy Index (FACT-VCI)[26; 27]. Only 1 MIBC study we 
evaluated used a bladder-specific questionnaire. Four of the 9 studies evaluated did not 
provide the rationale for PRO instrument used and 4 did not provide the validity or 
reliability of the instrument used. The purpose of disease-specific, validated questionnaires 
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is to capture PRO data meaningful to stakeholders for clinical decision-making. We believe 
that the dissemination of newer instruments will improve the quality of PRO reporting.
Much of the interest in PRO in bladder cancer has been comparing outcomes by urinary 
diversion type: ileal conduit, continent cutaneous or orthotopic neobladder. Understandably, 
there are no RCT comparing these diversions, and therefore, few RCT in MIBC. Prior to 
January 2004, there were no RCT evaluating PRO after radical cystectomy[9]. Of the 3 RCT 
we found in patients undergoing radical cystectomy, 1 examined techniques in orthotopic 
neobladder creation and 2 examined post-operative recovery and pain control.
Some of the weaknesses of PRO reporting in bladder cancer we found have previously been 
described[8; 9]. In the current review, only 3 studies reported baseline PRO data. Four 
studies did not provide the rationale for choice of the PRO instrument or the psychometric 
properties.
As in prostate and gynecological cancers, one of the main weaknesses of PRO reporting was 
in the handling of missing data.[10; 11] Missing data leads to reduced power and can be a 
significant source of bias. Missing data in PRO studies are often not random and can be 
associated with the outcome of interest. For example, patients completing a PRO survey 
after surgery may have considerable demographic and clinical differences compared to 
patients who chose not to complete the survey. The extent of missing data and the statistical 
handling of this data are, therefore, critical to understanding the generalizability of PRO 
findings.
This study highlights the current weaknesses of PRO reporting in bladder cancer RCTs. In 
contrast to previous systematic reviews, we used a formal, objective approach to evaluating 
PRO reporting in the bladder cancer literature. As has been demonstrated in similar reviews 
in prostate and gynecological cancers, high-quality PRO reporting can facilitate clinical 
decision-making and approval of beneficial interventions.[10; 11] When designing RCTs in 
bladder cancer, investigators should recognize the importance of including valid and reliable 
PROs in the trial protocol and the necessity for detailing the methodology of PRO 
assessment.
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Figure 1. 
Schematic breakdown of literature search results of bladder randomized controlled trials 
(PRO= patient-reported outcomes).
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